I
ITM Radiopharma
Radioisotopes and radiopharmaceuticals for cancer treatment
About ITM Radiopharma
ITM Isotope Technologies Munich (ITM Radiopharma) is a German radiopharmaceutical company headquartered in Garching near Munich that produces medical radioisotopes and develops targeted radiopharmaceutical therapies and diagnostics for cancer. Founded in 2004, the company has grown from an isotope manufacturer into a vertically integrated radiopharmaceutical business with a global distribution network spanning more than 65 countries.
ITM is a leading producer of therapeutic radioisotopes, most notably high-purity non-carrier-added lutetium-177, which it supplies to pharmaceutical companies, radiopharmacies and hospitals for both approved and investigational targeted radionuclide therapies. It is expanding into further isotopes including actinium-225 and terbium-161, supported by its NOVA production facility in Germany and the Actineer joint venture with Canadian Nuclear Laboratories, and it also provides radiolabelling equipment such as synthesizers and quality control systems.
Its drug pipeline focuses on precision oncology using the theranostic approach, in which a targeting molecule carries a radioisotope directly to tumour cells for imaging or treatment while sparing surrounding tissue. The lead candidate, ITM-11 (lutetium-177 edotreotide), has completed Phase 3 development for gastroenteropancreatic neuroendocrine tumours, and further programmes address glioblastoma, prostate cancer and other solid tumours.
The company generates revenue mainly from the sale of radioisotopes and related products to pharmaceutical partners and healthcare providers, alongside its proprietary drug development pipeline.
Source: Dealroom company dataNews
Open roles
ITM Radiopharma in the Garching bei München ecosystem
The ITM Radiopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- PEPetrichor
Series B and later10 investors entered at this stage
MedTech
European Investment Bank
China Grand Pharmaceutical and Healthcare Holdings
Temasek
Nextech Invest
Qatar Investment Authority
Carbyne Partners
BlackRock- AVATHOS Venture
Blue Owl Capital
Source: Dealroom Talent Intelligence.
Patents
14 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See ITM Radiopharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


